Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Analysis of Short-term (Operating) Activity Ratios

Microsoft Excel

Short-term Activity Ratios (Summary)

Celgene Corp., short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Turnover Ratios
Inventory turnover 1.28 0.85 0.88 0.95 0.98
Receivables turnover 7.39 6.75 6.90 6.45 6.48
Payables turnover 1.40 1.51 1.77 1.74 1.95
Working capital turnover 3.05 1.09 1.41 1.23 1.00
Average No. Days
Average inventory processing period 285 428 415 385 372
Add: Average receivable collection period 49 54 53 57 56
Operating cycle 334 482 468 442 428
Less: Average payables payment period 260 241 206 209 187
Cash conversion cycle 74 241 262 233 241

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Celgene Corp. inventory turnover ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.
Receivables turnover An activity ratio equal to revenue divided by receivables. Celgene Corp. receivables turnover ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Celgene Corp. payables turnover ratio decreased from 2016 to 2017 and from 2017 to 2018.
Working capital turnover An activity ratio calculated as revenue divided by working capital. Celgene Corp. working capital turnover ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Celgene Corp. number of days of inventory outstanding deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Celgene Corp. number of days of receivables outstanding deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.
Operating cycle Equal to average inventory processing period plus average receivables collection period. Celgene Corp. operating cycle deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Celgene Corp. number of days of payables outstanding increased from 2016 to 2017 and from 2017 to 2018.
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Celgene Corp. cash conversion cycle improved from 2016 to 2017 and from 2017 to 2018.

Inventory Turnover

Celgene Corp., inventory turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Cost of goods sold, excluding amortization of acquired intangible assets 587 461 438 420 386
Inventory 458 541 498 443 393
Short-term Activity Ratio
Inventory turnover1 1.28 0.85 0.88 0.95 0.98
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Inventory turnover = Cost of goods sold, excluding amortization of acquired intangible assets ÷ Inventory
= 587 ÷ 458 = 1.28

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Celgene Corp. inventory turnover ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.

Receivables Turnover

Celgene Corp., receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Net product sales 15,265 12,973 11,185 9,161 7,564
Accounts receivable, net of allowances 2,066 1,921 1,621 1,421 1,167
Short-term Activity Ratio
Receivables turnover1 7.39 6.75 6.90 6.45 6.48
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Receivables turnover = Net product sales ÷ Accounts receivable, net of allowances
= 15,265 ÷ 2,066 = 7.39

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Receivables turnover An activity ratio equal to revenue divided by receivables. Celgene Corp. receivables turnover ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.

Payables Turnover

Celgene Corp., payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Cost of goods sold, excluding amortization of acquired intangible assets 587 461 438 420 386
Accounts payable 418 305 247 241 198
Short-term Activity Ratio
Payables turnover1 1.40 1.51 1.77 1.74 1.95
Benchmarks
Payables Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Payables turnover = Cost of goods sold, excluding amortization of acquired intangible assets ÷ Accounts payable
= 587 ÷ 418 = 1.40

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Celgene Corp. payables turnover ratio decreased from 2016 to 2017 and from 2017 to 2018.

Working Capital Turnover

Celgene Corp., working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Current assets 9,067 14,892 10,868 9,401 9,713
Less: Current liabilities 4,057 2,987 2,959 1,969 2,112
Working capital 5,010 11,905 7,908 7,432 7,600
 
Net product sales 15,265 12,973 11,185 9,161 7,564
Short-term Activity Ratio
Working capital turnover1 3.05 1.09 1.41 1.23 1.00
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Working capital turnover = Net product sales ÷ Working capital
= 15,265 ÷ 5,010 = 3.05

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Working capital turnover An activity ratio calculated as revenue divided by working capital. Celgene Corp. working capital turnover ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.

Average Inventory Processing Period

Celgene Corp., average inventory processing period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data
Inventory turnover 1.28 0.85 0.88 0.95 0.98
Short-term Activity Ratio (no. days)
Average inventory processing period1 285 428 415 385 372
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.28 = 285

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Celgene Corp. number of days of inventory outstanding deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.

Average Receivable Collection Period

Celgene Corp., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data
Receivables turnover 7.39 6.75 6.90 6.45 6.48
Short-term Activity Ratio (no. days)
Average receivable collection period1 49 54 53 57 56
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 7.39 = 49

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Celgene Corp. number of days of receivables outstanding deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.

Operating Cycle

Celgene Corp., operating cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data
Average inventory processing period 285 428 415 385 372
Average receivable collection period 49 54 53 57 56
Short-term Activity Ratio
Operating cycle1 334 482 468 442 428
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 285 + 49 = 334

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Operating cycle Equal to average inventory processing period plus average receivables collection period. Celgene Corp. operating cycle deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.

Average Payables Payment Period

Celgene Corp., average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data
Payables turnover 1.40 1.51 1.77 1.74 1.95
Short-term Activity Ratio (no. days)
Average payables payment period1 260 241 206 209 187
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 1.40 = 260

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Celgene Corp. number of days of payables outstanding increased from 2016 to 2017 and from 2017 to 2018.

Cash Conversion Cycle

Celgene Corp., cash conversion cycle calculation, comparison to benchmarks

No. days

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data
Average inventory processing period 285 428 415 385 372
Average receivable collection period 49 54 53 57 56
Average payables payment period 260 241 206 209 187
Short-term Activity Ratio
Cash conversion cycle1 74 241 262 233 241
Benchmarks
Cash Conversion Cycle, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 2018 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 285 + 49260 = 74

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Celgene Corp. cash conversion cycle improved from 2016 to 2017 and from 2017 to 2018.